Back to Agenda
Session 1: New Developments and Updates from Health Canada
Session Chair(s)
Marcia Bailey, BSN, MHS, RN
Safety Evaluation and Risk Management Scientific Director
GSK, Canada
Gain a general overview of Vanessa’s Law (Bill C-17) and its potential impact on industry. Updates regarding Health Canada’s Risk Communication Process, specific Reporting Guidance Documents, and the Transparency Initiatives will be presented.
Speaker(s)
Vanessa’s Law - An Industry Perspective
Karyn Pellatt-Caron
Otsuka Canada Pharmaceutical Inc., Canada
Corporate Counsel
Proactive Pharmacovigilance - Risk Management Planning
Rania Mouchantaf, PhD
Health Canada, Canada
A/Executive Director, Marketed Pharmaceuticals Bureau, MHPD
Health Canada Transparency Initiatives - Safety Review (In Progress and Summaries)
Alain G. Musende, PhD
Marketed Health Products Directorate, Health Canada, Canada
Manager, Section for Transparency and Advertising Regulatory Surveillance
Health Canada Risk Communication Process Updates
Patricia Carruthers-Czyzewski, MSc, RPh
Health Canada, Canada
Manager, Risk Communication Section
Have an account?